Prompted by a recent report on declining incidence of sudden unexpected death in epilepsy (SUDEP) following implantation of a vagus nerve stimulator (VNS), we analyzed SUDEP risk over 6 years in a population-based cohort of 60 952 epilepsy patients in Sweden. All deaths from July 1, 2006 through December 31, 2011, were identified. Those with epilepsy mentioned on the death certificate were adjudicated for SUDEP using medical records and autopsy reports. In all, 292 SUDEP cases were identified. Comparing the first years (2006)(2007) with the subsequent 4 years (2008)(2009)(2010)(2011), the crude and standardized (to the US 2000 population) incidence of SUDEP (whether or not possible SUDEP was included) was significantly lower during the second time period; Incidence rate ratios based on standardized rates was estimated at 0.76 (95% confidence interval [CI] 0.60-0.97, P = .027) for SUDEP.
| INTRODUCTION
The incidence of sudden unexpected death in epilepsy (SUDEP) has been estimated to 0.2-1.4/1000 patient-years depending on age and sex. 1, 2 Estimates are higher if cases of possible SUDEP (where a competing cause of death is present and no autopsy has been performed) are included. 2 Previous population-based studies have not considered possible time trends in SUDEP incidence. 3 Knowledge regarding the evolution of SUDEP risk over time in patient cohorts is important for individual patient counseling as well as for the undertaking of surveillance of SUDEP risk on a population level, and thus for assessment of interventions aimed at reducing SUDEP risk.
In a recent study, Ryvlin and colleagues 4 presented for the first time the results of a long-term SUDEP surveillance after implantation of vagus nerve stimulator (VNS) in 40 443 patients with drug-resistant epilepsy. The authors reported a significant SUDEP rate decrease during the follow-up time up to 10 years after VNS implantation. However, in the absence of a control group, it was not possible to determine if the observed decline in SUDEP incidence was an effect of the VNS treatment or simply a reflection of the natural course of SUDEP risk in an epilepsy cohort. Because the latter is unknown, we have analyzed SUDEP risk over time in a large, population-based cohort of epilepsy patients in Sweden utilizing Swedish health care registries and with individual adjudication of all potential SUDEP cases.
| METHODS

| Standard protocol approvals
The study was approved by the ethics committee of Karolinska Institutet.
| Study population
The 
| SUDEP identification and adjudication
Our methods for identification and adjudication of SUDEP cases have been described in detail before. 2, 5 In short, all death certificates for all 1565 eligible patients were reviewed by one neurologist (OS), and obvious non-SUDEP deaths such as cancer, terminal illness, postmortem confirmed pneumonia, stroke, or myocardial infarction were excluded from further analysis (n = 736). When SUDEP could be the cause of death (n = 829), patient records from family physicians, hospital records, nursing homes or other institutions, police records, and autopsy records were reviewed (OS), and all information was extracted by a standardized protocol. Remaining potential SUDEP cases were reviewed by 2 neurologists (OS and TT) and classification of the cases was made through consensus.
| SUDEP definition and classification
SUDEP was defined as sudden, unexpected, witnessed or unwitnessed, nontraumatic, and nondrowning death of patients with epilepsy with or without evidence of a seizure, excluding documented status epilepticus, and in whom postmortem examination does not reveal a structural or toxicological cause for death. 6 We classified our SUDEP cases according to Annegers criteria 7 into 3 subgroups: (1) definite SUDEP when all clinical criteria are met, and an autopsy is performed that revealed no alternative cause of death; (2) probable SUDEP when all clinical criteria are met, but no autopsy is performed; and (3) possible SUDEP, when SUDEP could not be ruled out, but there is insufficient evidence regarding the circumstances of the death and no autopsy is performed.
| Statistical methods
To facilitate comparison, our primary statistical analyses were chosen to mimic closely the methods used in the recent VNS study. 4 4 Also following the method used in the VNS study, 4 we contrasted incidence during the last 4 years of follow-up against the 2 first years and calculated incidence rate ratios (IRRs), 95% confidence intervals (CIs), and two-tailed P-values. MannKendall nonparametric trend tests were used on the crude and standardized incidence rates. 9 In addition, we used a
Poisson model with a log link to estimate IRR and 95% CI by 1-year of follow-up, adjusted for age as at third-degree polynomial. SAS (SAS software, Version [9.4] 
| RESULTS
Demographics of the study population, the deceased during follow-up, and the SUDEP cases are presented in Table 1 . Mean age of the study population was 46.0 years and 52.5% were men. We identified 292 SUDEP cases during follow-up (151 definite, 84 probable, and 57 possible).
There was a male preponderance among the deceased, most pronounced among possible SUDEP. SUDEP cases died at a younger age than those who died for other reasons. Among SUDEP cases, definite SUDEP cases were younger than probable and possible SUDEPs.
Crude and standardized incidence of all-cause mortality and SUDEP by calendar year of follow-up are shown in Table 2 Table 2 ). The Mann-Kendall trend test was significant for all-cause mortality. By use of an age adjusted Poisson model the average decline per year was estimated at 3% (95% CI 2%-4%, P < .001) for all-cause mortality and 7% (95% CI 0%-13%, P = .040) for SUDEP ( Table 2 ).
| DISCUSSION
In this large population-based cohort study, we found a significant decrease in SUDEP incidence over time by approximately 7% per year, more pronounced than the observed decrease in all-cause mortality ( Table 2) . Using an analysis similar to the one in the recent VNS study, we found a SUDEP rate approximately 25% lower during the last 4 years of follow-up compared with the first 2 years (Table 2 ). This decrease is on par with the decline reported in the 10-year follow-up of epilepsy patients with VNS therapy. 4 There are some major differences between these studies. First, while the latter is based on a highly selected cohort with pharmacoresistant epilepsy, our cohort can be considered more representative of the general epilepsy population. Registration in SNPR is compulsory for patients hospitalized in any hospital in the country since 1987 and for any hospital-based outpatient visits since 2001. 10 Our cohort is thus likely to include most people with epilepsy in Sweden. The difference in study population probably explains the higher SUDEP rates in the VNS cohort compared to ours: 2.47/1000 patient-years in year 1-2 in the VNS cohort vs 1.16/1000 patient-years in our cohort, and 1.68/1000 patient-years in year 3-10 in the VNS cohort vs 0.87/1000 patient-years in year 3-6 in our cohort. Another difference was in duration of follow-up: median time 7.6 years in the VNS cohort and 6 years in our study. The validity of the Mann-Kendall test for trend
Incidence rate ratio per 1 y, (95% CI) | SUDEP diagnosis is a major difference between the studies. Our adjudication of potential SUDEP cases was more comprehensive, as we had access to all medical records and autopsy reports. These data were carefully reviewed for any death for which epilepsy was mentioned on the death certificate, and where SUDEP was a possibility. This is reflected in the fact that 80.2% of our cases were either definite or probable and only 19.8% possible SUDEP. In contrast, 84% of the SUDEP cases in the VNS study were classified as possible. 4 Our study has certain limitations. First, the study population was defined based on the inclusion in SNPR with and epilepsy ICD code. A previous review of a selected epilepsy cases in the SNPR indicated that approximately 10% do not fulfill epilepsy criteria.
2 Second, we lack information on the duration of epilepsy at start of follow-up among the patients included in our cohort. Third, only deaths for which epilepsy was mentioned on the death certificate were adjudicated in detail. We know from our previous study that this is the case in only 64% of SUDEP cases. 2 Our current report thus probably underestimates the SUDEP rate by about one-third. However, none of these limitations should have an impact on the time trends. A further limitation is the total number of SUDEP cases in our study, 292 compared with 632 in the VNS study. 4 Nonetheless, for definite and probable SUDEP, which usually are used for studies of SUDEP incidence, our study comprised more than twice as many cases as the VNS study (235 vs 101). The risk of SUDEP in VNS patients, and the possibility of a decrease of risk over time after implantation, has been discussed before based on smaller cohorts. 11, 12 Our observations indicate that the risk of SUDEP may decrease over time for people with epilepsy in general. The results thus suggest that a decline in risk may be related to a natural evolution or to a combination of the different interventions that patients with epilepsy are subjected to over time, rather than a single specific treatment such as VNS. In addition, it cannot be excluded that greater awareness in lay and medical communities about SUDEP during the time period could be a potential contributing factor. Previous research has indicated that there is an individual susceptibility to SUDEP among patients with epilepsy. 13 It is conceivable that patients with such susceptibility are more likely to die earlier during follow-up with those making up the remaining cohort at lower risk. Whatever the reason for a decrease in SUDEP rate with duration of follow-up, it is clear from our results that any study attempting to assess the effectiveness of an intervention against SUDEP needs to include a control group. A further conclusion is that epilepsy duration needs to be considered when reports of the incidence of SUDEP are interpreted, and that this will have implications for individual patient counseling of risks.
Finally, this as well as the VNS study 4 highlights the need to develop effective and reliable methods for SUDEP surveillance.
